Mirati Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing a pipeline of oncology products including candidates intended to treat specific genetic and epigenetic drivers of cancer in selected subsets of cancer patients with unmet needs. The Company's clinical pipeline consists of three product candidates: glesatinib, sitravatinib and mocetinostat. Both glesatinib and sitravatinib are orally-bioavailable, spectrum-selective kinase inhibitors with distinct target profiles that are in development for the treatment of patients with NSCLC and other solid tumors.

Type
Public
HQ
San Diego, US
Founded
2013
Size (employees)
38 (est)
Website
mirati.com
Mirati Therapeutics was founded in 2013 and is headquartered in San Diego, US
Report incorrect company information

Mirati Therapeutics Office Locations

Mirati Therapeutics has an office in San Diego
San Diego, US (HQ)
200 9393 Towne Centre Dr
Show all (1)
Report incorrect company information

Mirati Therapeutics Financials and Metrics

Mirati Therapeutics Financials

USD

Revenue (Q1, 2018)

9.5 m

Net income (Q1, 2018)

(14.7 m)

EBIT (Q1, 2018)

(15.3 m)

Market capitalization (15-Jun-2018)

1.6 b

Closing share price (15-Jun-2018)

49

Cash (31-Mar-2018)

20.6 m
Mirati Therapeutics's current market capitalization is $1.6 b.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

General and administrative expense

15.3 m13.5 m

R&D expense

68.5 m58.1 m

Operating expense total

83.8 m71.5 m

EBIT

(32 m)(39.1 m)(64.7 m)(83.8 m)(71.5 m)
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

Revenue

9.5 m

General and administrative expense

2.4 m2.9 m3.5 m3.8 m4.2 m4.2 m4.1 m3.8 m3.5 m3.7 m3.7 m5.2 m

R&D expense

5.2 m7.2 m7 m8.2 m11.3 m14.6 m18 m18.4 m16.1 m14.4 m15 m19.7 m

Operating expense total

8 m10.1 m10.5 m12 m15.5 m18.7 m22.1 m22.2 m19.6 m18.1 m18.6 m24.8 m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

14.2 m6.6 m49.5 m22.4 m107.7 m

Accounts Receivable

Inventories

Current Assets

64.2 m32.7 m125.4 m59.6 m155.8 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

Cash

7.6 m8.3 m8.5 m4.9 m14.3 m13.4 m109.9 m34.6 m24.5 m19.8 m29.8 m20 m20.6 m

Current Assets

17 m56 m49.2 m40.3 m71.2 m60.9 m141 m109.9 m93 m75.5 m107.9 m92.3 m153.1 m

PP&E

427 k275 k479 k524 k667 k693 k639 k601 k558 k537 k638 k618 k484 k

Total Assets

18 m56.3 m49.7 m41.3 m72.2 m61.9 m143.7 m112.5 m96 m79.2 m110.8 m95 m154.5 m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(43.7 m)(64.5 m)(83.1 m)(70.4 m)

Depreciation and Amortization

171 k199 k212 k180 k184 k

Inventories

Accounts Payable

(1.3 m)
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2018

Net Income

(13.7 m)(11 m)(8.6 m)(11.9 m)(15.4 m)(18.7 m)(21.9 m)(22.1 m)(19.4 m)(17.8 m)(14.7 m)

Depreciation and Amortization

105 k41 k

Cash From Operating Activities

(7.9 m)

Purchases of PP&E

(199 k)
USDY, 2018

Financial Leverage

1.1 x
Show all financial metrics

Mirati Therapeutics Operating Metrics

FY, 2016

Patents Issued

32

Patents Pending

1
Show all operating metrics
Report incorrect company information

Mirati Therapeutics Online and Social Media Presence

Embed Graph
Report incorrect company information

Mirati Therapeutics News and Updates

Histone Deacetylase 1 Market By top manufactures Mirati Therapeutics Inc., Oncolys BioPharma Inc.

Latest research study from HTF MI with title Global and United States Histone Deacetylase 1 by Manufacturers, Regions, Type and Application, Forecast to 2023. Posted via Industry Today. Follow us on Twitter @IndustryToday
Report incorrect company information